A case study was reported of a 46-year-old HIV positive woman who developed Hodgkin’s lymphoma and was initiated on ABVD chemotherapy (doxorubicin/bleomycin/vinblastine/dacarbazine, 46/18.6/11/700 mg, every two weeks). Due to concerns of a drug-drug interaction, her ART was switched from a regimen containing rilpivirine to elvitegravir/cobicistat/emtricitabine/tenofovir-DF (Stribild: 150/150/300/200 mg, once daily). After the first cycle, the patient reported paraesthesia of the legs and difficulty walking. After the third cycle she presented with sensory-motor lower and upper limbs peripheral neuropathy, which was confirmed by electromyogram. Vinblastine was stopped and replaced with 150 mg etoposide. Stribild was also stopped and replaced with ritonavir/abacavir/lamivudine/darunavir (100/600/300/800 mg, once daily). The neuropathies decreased after two weeks but persisted for a further six months. The authors hypothesise a drug-drug interaction occurred via inhibition of CYP3A4 by cobicistat, increasing vinblastine toxicity.